AmtixBio

Platform for the Development of Microbial Infectious Diseases and Related Diseases

• Key Element 1

  FADeRc

  Functionalized Amino Acids Derivative Repository (FADeR) Active Pharmaceutical Ingredient

  Key Point

  • New Chemical Entities (NCEs) with novel drug action mechanisms
  • Simple compound structures compared to competitive drugs
  • Structural scalability and rapid drug development through fragment-based drug discovery
  • Excellent drug properties and low production costs
  • Rapid drug development
  • Extensive and comprehensive patents
• Key Element 2

  TARO Vault

  Multi-Omics Integrated Virulence Factors Drug Target Database (TARget Omics, TARO Vault) Innovative Drug Targets (First-in-Class)

  Key Point

  • First-in-Class drug targets
  • DNA barcoding knockout mutant library construction technology based on Signature Tagging Mutagenesis (STM), enabling large-scale rapid processing and virulence factor discovery
  • Spore formation analysis methods for knock-down and heterozygous mutant strains
  • Multi-Omics analysis platform and drug target database
  • Target-based drug screening technology
  • Pipeline sustainability
• Key Element 3

  SAMH

  In Situ Self-Crosslinked Biocompatible Material (Self-Assembled Modified Hyaluronic Acids) Drug Delivery System

  Key Point

  • Excellent biocompatibility based on hyaluronic acid + differentiated physical and mechanical properties
  • Superior integration with biological tissues
  • Pipeline expansion through the development of various drug formulations (Gel, MN, MP)
  • Pipeline expansion through drug modality diversification
  • Stable cash flow and revenue realization through commercialization as medical devices such as dermal fillers

Interconnectivity of Key Elements Constituting the Core Technology

• Key Element 1 : FADeR
  Phrmaceutical API
• Key Element 2 : TARO Vault
  First-in-Class Drug Targets
• Key Element 3 : SAMH
  Indication Expansion, Technology Longevity

• New Small Molecule Compounds (API)
  (FADeR-6000 Class)
• First-in-Class Drug Target
  (FADeR-6000 Class)
• ATB1651
  Treatment for Onychomycosis/Tinea Pedis
• SAMH-Sol-ATB1651
  Treatment for Mucormycosis

• Key Element 1 :FADeR – Characteristics and Differentiation

  *FADeR : Functionalized Amino acid Derivatives Repository

  Functionalized Amino Acid Derivative-Based Small Molecule Compound Library

  • Superior drug properties of functionalized amino acid derivatives
  • Proven antimicrobial activity of amino acid scaffolds
  • Commercial success of functionalized amino acid derivative drugs
  • Scalability of functionalized amino acid derivatives using FOD (Fragment-Oriented Design)

  • Proven Antimicrobial Activity of Amino Acid Scaffolds Since Penicillin Derivatives
  • Commercial success of functionalized amino acid derivative drugs
  • Scalability through Fragment-Based Drug Discovery (FBDD)
  • Application of drug design methods using AI and deep learning-based medicinal chemistry software

  

  • New Small Molecule Compounds – API
  • Structural scalability – Pipeline expansion potential
  • Extensive product patents secured

• Key Element 2 :TARO Vault – Characteristics and Differentiation

  *TARO Vault : TARget Omics Vault

  Drug Target Database of Virulence Factors Integrated with Multi-Omics

  • Drug candidates and/or comparative drugs
  • Gene deletion mutants of drug targets
  • Multi-Omics analysis
  • TARO Vault integrated Omics database

  • First-in-Class Innovative Drug Targets
  • Pipeline sustainability and scalability
  • Rapid identification of drug targets
  • Target-based drug screening

  • DBKO Mutant Library (DBKO: DNA Barcoding Knockout Mutants)
    Virulence assessment based on STM (STM: Signature Tagging Mutagenesis
  • Creation of essential gene mutants (knockdown and overexpression)
    Determination of essential gene status (random spore analysis)

  • Virulent Factor Target
  • Fungistatic Target
  • Fungicide Target

  Multi-Omics Platform

  • Transcriptomics
  • Proteomics
  • Phosphoproteomics
  • Metabolomics
  • Glycomics
  • Phenomics

  Drug Target Database for Fungal Virulence Factors

  • Kinase targets
  • Phosphatase targets
  • Transcription factor targets
  • WD40 domain protein targets
  • Glycosylation targets
  • Multi-drug resistant Candida virulence factor targets
  • Blood-brain barrier (BBB) penetration-related protein targets

• Key Element 3 :SAMH – Characteristics and Differentiation

  *SAMH : Self-Assembled Modified Hyaluronic acids

  In situ Self-crosslinking Biocompatible Materials

  • Scalability to medical devices (e.g., dermal filler, anti-adhesive)
  • Comprehensive scalability across drug modalities
  • Sustained-release (SR) drug delivery
  • Diversity in formulation and administration pathways (Microparticle, Microneedle, Solution)

  • Enhancing competitiveness by extending the technological lifespan of products
  • Scalability of technology product pipelines
  • All-round scalability of drug modality
  • Securing a stable sales base early by commercializing medical device expansion technology products

  • SAMH-Sol
  • SAMH-MP
  • SAMH-MN

  • Differentiated physical and mechanical properties
  • Excellent biocompatibility
  • Diversity of formulation and administration pathways
  • Sustainable release drug delivery platform

Scalability of technology products

• Antifungal Treatments
  • Human
    medicine
    Onychomycosis
    ATB1651
  • Human
    medicine
    Multi-drug resistant bacterial infection treatment
    ASM0015
  • Agricultural
    antifungal
    Antifungal agent for crops
  • Animal
    medicine
    Antifungal Agents for Companion animals
    ATB1651
  • Human
    medicine
    Multi-drug resistant candidiasis
    ATC0001
  • Human
    medicine
    Aspergillosis, Mucormycosis
    ATB6013, ATB1651
  • Human
    medicine
    Fungal skin infection
    ATB1651
• Treatments for Microbial Infection-Related Disease
  • Human
    medicine
    Atopic dermatitis
    ATB1606
  • Human
    medicine
    Asthma
    ATB1606
  • Human
    medicine
    Paregoric
    ATB1091
  • Animal
    medicine
    Treatment for animal dermatitis
    ATB1606
  • Human
    medicine
    Pruritus
    ATB1606
  • Human
    medicine
    Psoriasis
    ATB1606
• SAMH (Biocompatible Materials)
  • Medical
    device
    Dermal filler
    SAMH, Eiinesfyl
  • Human
    medicine
    Sustained release drug delivery system
    SAMH-Sol-ATB1651, SAMH-MP-SEMA
  • Human
    medicine
    Tissue engineering scaffold
    SAMH, Scaffold
  • Cosmetics
    Microneedle patch
    SAMH-MN
  • Human
    medicine
    Vaccine adjuvant
    SAMH-MP
  • Medical
    device
    Anti-adhesive
    SAMH-Sol